MINNEAPOLIS, Feb. 23, 2017 /PRNewswire/ -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company that develops,manufactures and markets innovative proprietary products for the urology market, will release financial results for the fourth quarter and fiscal year ended December 31, 2016 before the market open on Thursday,
The Company will host a conference call and webcast to discuss its financial results the same day on Thursday, March 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Darin Hammers, President and Chief Executive Officer, will host the event along with Brett Reynolds, Chief Financial Officer. Individuals wishing to participate in the conference call should dial 877-303-1595 with the conference ID number 78544327. To access a live webcast of the call, go to the investor relations section of Cogentix Medical's website at ir.cogentixmedical.com.
An audio replay will be available for 30 days following the call at 855-859-2056 with the conference ID number 78544327. An archived webcast will also be available at ir.cogentixmedical.com.
About Cogentix Medical Cogentix Medical, Inc., headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company. We design, develop, manufacture and market products for flexible endoscopy with our unique product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier, known as PrimeSight, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. We also commercialize the Urgent® PC Neuromodulation System, an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Cogentix Medical and our products, please visit us at www.cogentixmedical.com. 'CGNT-G'
For Further Information: Cogentix Medical, Inc. Brett Reynolds, SVP and CFO 952-426-6152
EVC Group Doug Sherk/Brian Moore (Investors) 415-652-9100/310-579-6199
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cogentix-medical-to-report-fourth-quarter-results-on-march-9-2017-300412805.html
SOURCE Cogentix Medical, Inc.
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All